beta‐lactam monotherapy vs beta‐lactam (cloxacillin) plus aminoglycoside (gentamicin): All cause mortality
beta‐lactam monotherapy showed no clear difference in all cause mortality compared with beta‐lactam‐aminoglycoside combination therapy (high certainty).
What each review found
Current versions only| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
beta‐lactam monotherapy vs beta‐lactam‐aminoglycoside combination therapy All cause mortality · febrile neutropenic cancer patients. beta‐lactam monotherapy showed no clear difference in all cause mortality compared with beta‐lactam‐aminoglycoside combination therapy (high certainty). Beta‐lactam versus beta‐lactam‐aminoglycoside combination therapy in cancer patients with neutropenia (2013) · Cochrane Headline outcomes only | RR 0.87 [0.75, 1.02] | 44 studies · 7186 participants | High |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Beta‐lactam versus beta‐lactam‐aminoglycoside combination therapy in cancer patients with neutropenia 2013 · Cochrane Headline outcomes only | Not reported | list not extracted yet | Not assessed |
Studies behind the findings
None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.